---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-25-000021"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:23:34.522833+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MoonLake Q3 2025: $380.5M cash, positive Phase 2 PPP data for Sonelokimab

## Summary
- Cash and equivalents $380.5M as of Sept 30, 2025; runway into H2 2027.
- R&D expenses $60.6M (up from $49.8M) driven by trial ramp-up and BLA prep.
- Phase 2 LEDA PPP: 64% mean PPPASI reduction, 39% PPPASI75 at week 16; no approved therapies.
- VELA-TEEN interim: 46% HiSCR75 in adolescent HS at week 16 (n=11); BLA submission Q3/Q4 2026.
- FDA Type B meeting Dec 15, 2025 to discuss SLK in HS evidence for BLA.

## SEC filing metadata
- accession: 0001821586-25-000021
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/0001821586-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158625000021/mnlk-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-25-000021
- JSON: https://secwatch.observer/filing/0001821586-25-000021.json
- Plain text: https://secwatch.observer/filing/0001821586-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.